Urinary Bladder Neoplasms
📧 Sign up to get email alerts when something new happens for Urinary Bladder Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2021-10-20EMA Application withdrawn: Oportuzumab monatox DLRC Pharma Services (oportuzumab monatox) — DLRC Pharma Services Ltd
The EMA has withdrawn the application for oportuzumab monatox, submitted by DLRC Pharma Services Ltd, for urologic and urinary bladder neopl…
-
CLINICAL_TRIALS withdrawal · 2015-04-01Clinical Trial Update: SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I [Phase 3]
Phase 3 trial SHTC EUROPE-1 evaluating Synergo hyperthermia-chemotherapy for urinary bladder neoplasms has been withdrawn.